Please login to the form below

Not currently logged in
Email:
Password:

Janssen’s UK head moves to China

Cesar Rodriguez appointed managing director of Xian Janssen
Janssen Cesar Rodriguez.

Janssen's managing director for the UK and Ireland has moved to a new role in China.

Cesar Rodriguez has been named managing director and president of Xian Janssen, the Chinese subsidiary of Johnson & Johnson's pharma division Janssen.

The move marks another step in a well-travelled career for Rodriguez, which includes spells in Spain, Romania and, during the Arab Spring, Egypt.

At his most recent role in the UK, Rodriguez's significant accomplishments included leading Janssen as the top-ranked pharma company in The Sunday Times' Best Companies To Work For in 2012 and achieving a 100 per cent success rate with NICE in 2013.

The company also won The Accenture Award for PMEA Company of the Year at PMEA 2013 last week.

Kim Taylor, company group chairman, Janssen Pharmaceuticals, Asia Pacific, praised the experience of Rodriguez.

She said: “With almost two decades of work experience at Janssen in various commercial and senior leadership roles, Cesar will bring to the company in-depth understanding and insights on business strategy, a track record of delivering business growth in highly complex and diverse markets, and a career-long commitment to integrity and talent development.”

Rodriguez said he was looking forward to the challenges offered by a new market.

He said: “China faces tremendous unmet medical need, and I am excited to be joining Xian Janssen at a time when we are in an unparalleled position to serve that need and to bring important life-saving drugs to patients and families who need them.”

5th December 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...